Insights
- FIPA
- New ‘Sunshine Act’ Requirements Will Track and Publish Financial Relationships Providers Have with Healthcare Vendors
- While ACO Care Coordination Holds Promise for Improving Quality and Lowering Healthcare Costs, It’s Still a ‘Work in Progress
- Is a Patient-Centric Approach to Clinical Laboratory Management the Best Way to Move from Volume to Value?
- Whole-Genome Sequencing, Offers Quick, Accurate Test for Diagnosing Diseases Caused by Single-Gene Mutations
- Opportunities for Engagement by Clinical Laboratories and Pathologists
- UnitedHealthcare Partners to Form Large, Multi-System ACO in Wisconsin
- American Esoteric Laboratories Partner with the Department of Defense
- Revisiting the Benefits of Outsourcing Courier and Logistics Needs
- HIPAA Violation Fines Increase - How to Avoid
- Interface Fees & The High-Cost Charged By EHR Companies
- PathX LIS Earns High Marks From TissuePathology.com
New ‘Sunshine Act’ Requirements Will Track and Publish Financial Relationships Providers Have with Healthcare Vendors
Some physicians fear disclosure of payments by drug and medical device companies could damage patient confidence and physician-patient relationships
Over the course of 2014, pathologists and medical laboratory managers will experience a different relationship with in vitro diagnostic (IVD) manufacturers and other lab industry vendors. That’s because a new federal law requires vendors to publicly disclose financial and other arrangements they have with providers.
That law is the Physician Payment Sunshine Act, and it became effective on August 21, 2013. The intent of this new law is to shed light on financial aspects of relationships between physicians and healthcare vendors.
Read more: Attention Pathologists and Clinical Laboratory Professionals: New ‘Sunshine Act’ Requirements Will Track and Publish Financial Relationships Providers Have with Healthcare Vendors | Dark Daily
Powered By